CHIANG, EN PEI ISABEL,蒋恩沛,蔣恩沛,WU, YI TING,吴伊婷,吳伊婷,YEP, LAI PING,叶丽冰,葉麗冰,YEN, GOW CHIN,颜国钦,顏國欽
申请号：
TW098137662
公开号：
TWI421081B
申请日:
2009.11.05
申请国别(地区):
TW
年份:
2014
代理人:
摘要：
System of the present invention closes what dehydrogenation hydroxylation corticoid (prednisolone) what and increases the purposes of folic acid concentration and attenuating homocysteine concentration in blood plasma. The discovery of the base what present invention, dehydrogenation is hydroxylated corticoid for the folic acid supplement as adhib antiphlogistic or immunosuppressor patient, and for treating or preventing the disease as caused by folic acid deficiency in what body, such as homocysteine mass formed by blood stasis (homocysteinemia) and cardiovascular disease (cardiovascular diseases) etc. with what.本發明係關於去氫羥化腎上腺皮質素(prednisolone)用於增加血漿中葉酸濃度及減低同半胱胺酸濃度之用途。基於本發明之發現，去氫羥化腎上腺皮質素可供做為須服用消炎劑或免疫抑制劑患者之葉酸補充劑，以及可供用於治療或預防由於體內葉酸缺乏所引起的疾病，例如同半胱胺酸血症(homocysteinemia)及心血管疾病(cardiovascular diseases)等。
